Top

Published in:

01-01-2009 | Original Article

The treatment outcome of patients undergoing breast-conserving therapy: the clinical role of postoperative radiotherapy

Authors: Atsushi Oouchi, Koh-ichi Sakata, Hideji Masuoka, Mitsuharu Tamakawa, Hisayasu Nagakura, Masanori Someya, Kensei Nakata, Kazuaki Asaishi, Minoru Okazaki, Yutaka Okazaki, Tousei Ohmura, Masato Hareyama, Masakazu Hori, Izuru Shimokawara, Akira Okazaki, Yoshiki Watanabe, Tsuyoshi Yamada, Tomokazu Yuyama, Taishi Satoh, Koichi Hirata

Published in: Breast Cancer | Issue 1/2009

Abstract

Background

Treatment outcome was evaluated in patients who underwent breast-conserving therapy and tangential irradiation. After verifying background factors including systemic therapy, the clinical efficacy of postoperative irradiation was investigated.

Method

There were 708 study subjects, all of whom had early breast cancer treated between 1992 and 2002. The median follow-up period was 83 months. After breast-conserving surgery, in patients with negative surgical margins, only tangential irradiation at 48 Gy/24 fr was performed. In contrast, in those with positive surgical margins, 10 Gy of radiation boost to the tumor bed with electrons was administered after tangential irradiation with 50 Gy/25 fr. Treatment outcome was analyzed using the Kaplan–Meier method and Cox’s proportional hazards regression model.

Results

The disease-free survival and no-recurrence rates within the ipsilateral breast after 5 years were 93.4 and 97.2%, respectively. Risk factors for recurrence within the ipsilateral breast included younger age of patient, the number of positive lymph nodes, and no endocrine therapy. However, the surgical margin was not a risk factor. Risk factors for relapse outwith the ipsilateral breast included younger age, the number of positive lymph nodes, and recurrence within the ipsilateral breast.

Conclusions

From our analysis of 708 Japanese women who received breast-conserving therapy, which can be regarded as a standard method in Japan, the treatment outcome was compatible with previous reports from other countries.

Moriguchi Y, Mise K, Kan N, Yamabe H, Hiraoka M, Kodama H. Long-term results of breast-conserving therapy (BCT) with special reference to ipsilateral breast tumor recurrence at Kodama Breast Clinic. Nyuugan no Rinsyou. 2006;21:159–64. in Japanese with English abstract.

Part 3. Nyuusen syuyou no soshiki-gaku-teki-bunrui. In: The Japanese Breast Cancer Society editor. General rules for clinical and pathological recording of breast cancer. 15th ed. Kanehara Syuppan, Tokyo; 2004. pp 31–68.

Ohkawa T, Kodama H, Akiyama H, Itou Y, Inaji H, Ohuchi N, et al. Nyuubou-Onzonryouhou Gaidorain (1999). Nyuugan no Rinsyou. 2000;15:147–56. in Japanese.

Noh WC, Paik NS, Kim MS, Yang KM, Cho CK, Choi DW, et al. Ipsilateral breast tumor recurrence after breast-conserving therapy: a comparison of quadrantectomy versus lumpectomy at single institution. World J Surg. 2005;29:1001–6.PubMedCrossRef

Arriagada R, Lê MG, Contesso G, Guinebretière JM, Rochard F, Spielmann M. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol. 2002;13:1404–13.PubMedCrossRef

Kodaira T, Fuwa N, Itho Y, Matsumoto A, Kamata M, Furutani K, Sasaoka M, Miura S, Takeuchi T. Aichi Cancer Center 10-year experience with conservative breast treatment of early breast cancer: retrospective analysis regarding failure pattern and factors influencing local control. Int J Radiat Oncol Biol Phys 2001;49:1311–6.PubMed

Leong C, Boyages J, Jayasinghe UW, Bilous M, Ung O, Chua B, et al. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast cancer. Cancer. 2004;100:1823–32.PubMedCrossRef

Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH. The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys 2003;57:724–31.PubMed

Schnitt SJ, Abner A, Gelman R, Connolly JL, Recht A, Duda RB, et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast conserving therapy. Cancer. 1994;74:1746–51.PubMedCrossRef

10.

Gage I, Schnitt SJ, Nixon AJ, Silver B, Recht A, Troyan SL, et al. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer. 1996;78:1921–8.PubMedCrossRef

11.

Freedman G, Fowble B, Hanlon A, Nicolaou N, Fein D, Hoffman J, et al. Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. Int J Radiat Oncol Biol Phys 1999;44:1005–15.PubMed

12.

Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000;18:1668–75.PubMed

13.

Obedian E, Haffty BG. Negative margin status improves local control in conservatively managed breast cancer patients. Cancer J Sci Am 2000;6:28–33.PubMed

14.

Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378–87.PubMedCrossRef

15.

Jhingran A, Kim JS, Buchholz TA, Katz A, Strom EA, Hunt KK, et al. Age as a predictor of outcome for women with DCIS treated with breast-conservating surgery and radiation: The University of Texas M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 2002;53:868–79.

16.

Polgar C, Fodor J, Orosz Z, Major T, Takácsi-Nagy Z, Mangel LC, et al. Electron and high-dose-rate brachytherapy boost in the conserving treatment of satge I–II breast cancer: first results of the randomized Gudapest boost trail. Strahlen Onkol. 2002;178:615–23.CrossRef

17.

Frazier TG, Wong RW, Rose D. Implications of accurate pathologic margins in the treatment of primary breast cancer. Arch Surg 1989;124:37–8.PubMed

18.

Horiguchi J, Iino Y, Takei H, Maemura M, Yokoe T, Niibe H, et al. Surgical margin and breast recurrence after breast-conserving therapy. Oncol Rep 1999;6:135–8.PubMed

19.

Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancer of one centimeter or less. J Clin Oncol. 2002;20:4141–9.PubMedCrossRef

20.

Vujovic O, Yu E, Cherian A, Dar AR, Stitt L, Perera F. Eleven-year follow-up in the delay of breast irradiation after conservative breast surgery in node-negative breast cancer patients. Int J Radiat Oncol Biol Phys. 2006;64(3):760–4.PubMed

21.

Vujovic O, Cherian A, Yu E, Dar AR, Stitt L, Perera F. The effect of timing of radiotherapy after breast-conserving surgery in patients with positive or close resection margin, young age, and node-negative disease, with long term follow-up. Int J Radiat Oncol Biol Phys. 2006;66:687–90.PubMed

22.

Inaji H, Akiyama F, Iino Y, Iino Y, Ikeda T, Ohsumi S, Tanaka AS, Kinoshita T, Murakami S. 13-9 Cyouki no tsuiseki kekka ni motozuku nyuugan ni taisuru tekiseina nyuubou onzon ryouho no kakuritu ni kansuru kenkyuu. Kouseiroudousyhou Gan-kenkyu-jyosei-kin niyoru kenkyu houkoku syu Heisei 13nen 402–406, 2001 (in Japanese).

23.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trial. Lancet. 2005;366:2087–106.PubMed

24.

Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004;96:115–21.PubMedCrossRef

Title: The treatment outcome of patients undergoing breast-conserving therapy: the clinical role of postoperative radiotherapy
Authors: Atsushi Oouchi
Koh-ichi Sakata
Hideji Masuoka
Mitsuharu Tamakawa
Hisayasu Nagakura
Masanori Someya
Kensei Nakata
Kazuaki Asaishi
Minoru Okazaki
Yutaka Okazaki
Tousei Ohmura
Masato Hareyama
Masakazu Hori
Izuru Shimokawara
Akira Okazaki
Yoshiki Watanabe
Tsuyoshi Yamada
Tomokazu Yuyama
Taishi Satoh
Koichi Hirata
Publication date: 01-01-2009
Publisher: Springer Japan
Published in: Breast Cancer / Issue 1/2009
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-008-0079-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Minimally invasive technology in the management of breast disease

Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin–docetaxel neoadjuvant chemotherapy: a cohort study

Whole-breast volume perfusion images using 256-row multislice computed tomography: visualization of lesions with ductal spread

International exchange activities with East Asian countries through mammography

Axillary mass suspected to be occult breast carcinoma: a case study of skipped axillary lymph node metastasis from endometrial carcinoma in which core-needle biopsy was useful for diagnosis

Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report

Keynote webinar | Spotlight on antibody–drug conjugates in cancer